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Abstract 
Background: Mendelian randomization (MR) studies have demonstrated strong support 
for an association between genetically increased body mass index and risk of MS. The 
adipokine adiponectin may be a potential mechanism linking body mass to risk of MS. 
Objective: To evaluate whether genetically-increased adiponectin levels influence risk of 
MS. Methods: Using genome-wide significant single nucleotide polymorphisms (SNPs) 
for adiponectin, we undertook an MR study to estimate the effect of adiponectin on MS. 
This method prevents bias due to reverse causation and minimizes bias due to 
confounding. Sensitivity analyses were performed to evaluate the assumptions of MR. 
Results: MR analyses did not support a role for genetically-elevated adiponectin in risk of 
MS (OR = 0.93 per unit increase in natural-log-transformed adiponectin, equivalent to a 
two-standard deviation increase in adiponectin on the absolute scale; 95% CI: 0.66-1.33; 
p = 0.61). Further MR analysis suggested that genetic variation at the adiponectin gene, 
which influences adiponectin level, does not impact MS risk. Sensitivity analyses, 
including MR-Egger regression, suggested no bias due to pleiotropy. Conclusion: 
Lifelong genetically-increased adiponectin levels in humans have no clear effect on risk 
of MS. Other biological factors driving the association between body mass and MS 
should be investigated. 
Introduction 
Multiple sclerosis is the most common chronic inflammatory disease of the central 
nervous system (1), affecting an estimated 2.3 million people worldwide (2). MS is 
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thought to be initiated by T-cells which target self-antigens in the CNS, resulting in 
demyelination and progressive neuroaxonal injury and degeneration (1). Disease onset 
usually occurs in early adulthood, and prognosis is variable; however, the disease is often 
progressively debilitating (3).  
 
Both genetic and environmental factors have been implicated in the etiology of MS (4). 
Genetic risk profiles in individuals with MS are often complex, and many non-genetic 
factors have been associated with the disease (4), including body weight. High BMI 
during childhood and early adolescence has been associated with a 1.15-1.18-fold 
increased risk of MS in adulthood (5), and overweight and obesity in late adolescence 
and early adulthood have been associated with an approximate two-fold increased risk of 
MS in adulthood (6,7). Furthermore, childhood overweight and obesity have been 
associated with an approximate 1.5- to 3.75-fold increased odds of pediatric-onset MS, 
depending on the extent of overweight or obesity (8). In addition, recent Mendelian 
randomization (MR) analyses have demonstrated support for a causal association 
between body mass index (BMI) and MS, whereby an increase in BMI by approximately 
5 kg/m2 increased the odds of MS by 40% (9). However, the underlying biological 
mechanisms linking BMI to MS are unclear.  
 
Obesity is associated with chronic, mild inflammation characterized by abnormal 
cytokine production and increased pro-inflammatory signaling. Adipose tissue is known 
to produce cytokines, known as adipokines; however, the relative contribution of 
adipocyte-derived cytokines to the inflammatory state in obesity is unknown (10). 
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Interestingly, adiponectin, an adipokine with known anti-inflammatory properties in both 
the innate and adaptive arms of the immune system (10), is reduced in overweight and 
obese individuals (11,12), and is negatively correlated with BMI (11). 
 
In light of these findings, animal and human studies alike have been undertaken to better 
understand adiponectin’s role in MS etiology and treatment. Results from studies using 
experimental autoimmune encephalomyelitis models of MS are suggestive of a protective 
role for adiponectin in rodents (13,14). However, findings from studies in clinical 
populations are diverse. One study showed reduced levels of this adipokine in peripheral 
blood of MS patients following acute relapse (15), while others demonstrate elevated 
adiponectin in peripheral blood and CSF of patients in remission (16,17), or unaltered 
adiponectin in newly diagnosed MS patients (18). 
 
Observational studies, such as those described above, represent an important step in the 
identification of risk factors in disease. Randomized control trials (RCTs) and/or MR 
studies can help to clarify the roles of identified risk factors in disease outcome, as 
findings of observational studies may be biased due to residual confounding and/or 
reverse causation. Indeed, numerous RCTs and MR studies have provided strong 
evidence for the presence of bias in previously reported observational associations (many 
examples reviewed in 19). However, these types of studies can also validate 
observational associations through demonstration of causality (also reviewed in 19). One 
such MR study (9) suggested that previously reported observational associations between 
body weight and MS (e.g. 5-8) are not likely biased due to confounding or reverse 
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causation. Nonetheless, no study to date has provided such evidence for the reported 
observational association between adiponectin level and MS. Confounding due to reverse 
causation is of particular concern in epidemiological studies of MS, as timing of disease 
onset is unknown. Therefore the nature of adiponectin’s role in MS etiology therefore 
merits further investigation. 
 
In the absence of experimental studies investigating adiponectin’s role in MS clinical 
populations, MR studies can be conducted to evaluate adiponectin’s role in disease 
outcome in a manner that allows for causal inference. This approach is conceptually 
similar to a randomized control trial, where instead of randomization to a pharmaceutical 
intervention, individuals in the population are naturally randomized at conception to 
varying levels of an exposure (e.g. adiponectin level) due to genetic variation.  
 
MR is a technique which uses genetic variants strongly associated with an exposure (e.g. 
adiponectin level) to estimate the exposure’s effect on disease risk (e.g. MS) (20). Since 
genetic variants are randomly allocated at meiosis, they are not influenced by 
confounding factors that may bias observational associations, except confounding by 
ancestry. Further, reverse causation is overcome since allelic randomization always 
precedes MS onset. 
To better understand whether adiponectin levels may influence risk of MS, we undertook 
an MR study of adiponectin on MS risk using a two-sample MR design, deriving the 
effects of single nucleotide polymorphisms (SNPs) on adiponectin and MS risk from the 
largest adiponectin and MS samples available to date: the ADIPOGen Consortium (N = 
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45,891) (21), the International Multiple Sclerosis Genetics Consortium (IMSGC, ncases = 
14,498 / ncontrols = 24,091) (22), and the IMSGC/Wellcome Trust Case Control 
Consortium 2 (IMSGC/WTCCC2, ncases = 9,772 / ncontrols = 17,376) (23). 
Methods 
SNP Selection, Effect Sizes, and Data Sources 
Genome-wide significant (p < 5 x 10-8) genetic variants associated with adiponectin 
levels were obtained from ADIPOGen (21). For this study, we limited our selection of 
SNPs and summary statistics to those that achieved genome-wide significance in the 
European sex-combined discovery phase analyses or joint analyses (30,708 ≤ n ≤ 
38,276). The effect of each SNP on natural-log-transformed adiponectin levels was 
adjusted for age, sex, BMI, the principle components of ancestry, study site (where 
appropriate), and family structure in cohorts with family members (21). Corresponding 
effect estimates of the adiponectin-associated SNPs on risk of MS were obtained first 
from the IMSGC Immunochip study, the largest genetic association study for MS (14,498 
cases and 24,091 controls) (22), and then from the second largest study, the 
IMSGC/WTCCC2 (9,772 cases and 17,376 controls) (23), if an adiponectin-associated 
SNP was not ascertained in the IMSGC Immunochip study. We have previously used 
these datasets to explore the effects of BMI and vitamin D on risk of MS (9, 24). If 
summary statistics were not available for an index SNP in either study, a highly 
correlated proxy (r2 > 0.8) was selected first from the Immunochip study and then from 
the IMSGC/WTCCC2 study, if the former was unavailable. Linkage disequilibrium (LD) 
for proxies was measured using UK10K samples (n = 3,781) (25).    
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SNP Validation 
Linkage disequilibrium assessment. MR studies require that the SNPs not be in LD, since 
strong correlations between selected SNPs may bias results (20). To ensure that the 
adiponectin-associated SNPs met this requirement, LD was measured between all 
selected SNPs using European samples from the UK10K project using PLINK software 
version 1.90 (25). SNPs were excluded from analyses if their measured LD was r2 > 0.05. 
Pleiotropy assessment. MR analyses assume that the SNPs influence the outcome (MS) 
solely through the exposure of interest (adiponectin). To assess for the presence of 
pleiotropy, MR-Egger regression was performed as previously described (27). This 
approach is based on Egger regression, which has been used to examine publication bias 
in the meta-analysis literature (28). In brief, the SNP’s effect upon the exposure variable 
is plotted against its effect upon the outcome, where an intercept distinct from the origin 
provides evidence for pleiotropic effects. Funnel plots can also be used for visual 
inspection of symmetry. In addition, a systematic PubMed literature search was 
conducted to investigate possible pleiotropic mechanisms of the selected SNPs on MS, 
using a previously described method (24) (S1 Methods). Last, pleiotropy was assessed 
by examining only the SNP at ADIPOQ, which encodes adiponectin. Pleiotropy is less 
likely to influence results at this locus, since it is likely that genetic variation at ADIPOQ 
influences adiponectin levels directly (29). 
Population Stratification. To reduce this potential source of bias, selected SNPs and 
summary statistics for both adiponectin and MS were obtained from analyses involving 
individuals of European descent only. In addition, a literature search was conducted to 
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investigate potential residual population stratification that may exist among European 
subgroups with respect to adiponectin levels (30). To the best of our knowledge, no 
epidemiological studies have investigated adiponectin levels across European subgroups; 
therefore, mean adiponectin serum concentrations from the ADIPOGen European cohorts 
were compared to investigate potential differences in population adiponectin levels across 
Europe.  A Shapiro-Wilks test was used to assess normality of mean adiponectin 
concentration for the following countries: United Kingdom, United States, Netherlands, 
Germany, Italy, and Finland. Analysis of variance (ANOVA) was then performed to 
investigate potential differences in adiponectin concentrations across these countries. 
Shapiro-Wilks test and ANOVA were performed using Graphpad Prism 6 software 
(GraphPad Soſtware Inc., La Jolla, CA, USA). 
 
Mendelian Randomization Estimates 
In this previously described two-sample MR study design (24,31) where independent 
SNPs evaluate the association of exposure to genetically altered adiponectin levels with 
MS risk, MR estimates were obtained by weighting each of the adiponectin-associated 
SNPs by the magnitude of its effect upon natural-log-transformed adiponectin level. The 
individual estimates were then meta-analysed using a fixed-effects model to obtain a 
summary measure for the effect of genetically increased adiponectin on risk of MS.  
 
Sensitivity Analyses 
If a given SNP violated any of the underlying assumptions of MR, MR estimates were re-
calculated excluding that SNP. Further sensitivity analyses were undertaken using (1) 
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only the lead SNP from ADIPOGen, located near the adiponectin-encoding gene 
ADIPOQ, to reduce potential bias from pleiotropy (29); and (2) only the SNPs genotyped 
in both ADIPOGen and either of the MS studies, to reduce potential bias from random 
error introduced by use of proxy SNPs 
 
All statistical analyses were performed using R version 3.2.2 software (32) unless 
otherwise noted. 
 
Results 
SNP Selection  
ADIPOGen identified 12 SNPs as genome-wide significant (p < 5 x 10-8) for adiponectin 
level in European populations (21). Of these, none were genotyped directly in the 
Immunochip study; however four were found in the IMSGC/WTCCC2 GWAS:  
rs1108842 (within GNL3), rs12922394 (within CDH13), rs1597466 (near TSC22D2), and 
rs2925979 (within CMIP) (Table 1). Proxies (r2 > 0.80) were identified for 6 of the 8 
remaining SNPs: one from the IMSGC Immunochip study (rs6810075, near the 
adiponectin-encoding gene ADIPOQ), and five from the IMSGC/WTCCC2 GWAS 
(rs2980879, near TRIB1; rs601339, near GPR109A; rs7133378, within DNAH10; 
rs7955516, near PDE3A; and rs3001032, near LYPLAL1) (Table 1). Therefore, 10 of the 
12 ADIPOGen SNPs were selected for this MR study. None of the ten adiponectin 
increasing alleles were significantly associated with MS risk, accounting for multiple 
testing (all p > 0.05/10 = 0.005, Table 1 and Figure 1). 
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SNP Validation 
Linkage disequilibrium. None of the 10 adiponectin-associated SNPs were found to be in 
LD (all pairwise r2 < 0.05) in the UK10K European samples (25).   
Pleiotropy. MR-Egger regression analyses suggested that pleiotropy did not greatly 
influence the results of the MR analyses (Egger intercept p = 0.21; 95% CI: -0.015-
0.058). Additionally, a literature review failed to unearth pleiotropic mechanisms for any 
of the investigated SNPs, with the exception of rs12922394. This SNP is located within 
an intron of the CDH13 gene, which encodes T-cadherin, a protein known to bind both 
high molecular weight (HMW) adiponectin and low-density lipoprotein (LDL). It is 
thought that T-cadherin might function as a receptor for both these ligands (33). 
Numerous epidemiological studies have demonstrated associations between elevated 
serum LDL and MS disease progression, as well as adverse clinical and MRI outcomes 
(34). Based on these findings, the possibility that CDH13 functions independently of 
adiponectin to produce MS phenotypes could not be eliminated; therefore, sensitivity 
analyses were undertaken to exclude rs12922394 from MR analyses.  
Population Stratification. A one-way ANOVA revealed that serum log-transformed 
adiponectin concentrations did not differ across the European subpopulations interrogated 
in ADIPOGen (F(5,17) = 1.27, p = 0.32). 
 
Mendelian Randomization Estimates 
Employing a fixed-effects model including all ten adiponectin-altering alleles revealed 
that a one-unit increase in natural-log-transformed adiponectin, which corresponds to a 2-
standard deviation (SD) change on the absolute scale, was not associated with a clear 
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effect on the odds of MS (OR = 0.93; 95% CI: 0.66-1.33; p = 0.61) (Figure 1). The I2 
estimate of heterogeneity was 0%, suggesting no heterogeneity of effect. Sensitivity 
analyses excluding rs12922394 (CDH13) for possible pleiotropic effects did not 
influence these results (OR = 0.93; 95% CI: 0.64-1.37; p = 0.72). Analysis of the 
ADIPOQ variant rs6810075 alone revealed that a one-unit increase of natural-log-
transformed adiponectin did not alter the odds of MS (OR: 0.60; 95% CI: 0.34-1.07; p = 
0.08). Analysis of the pooled non-proxy SNPs rs1108842, rs12922394, rs1597466 and, 
rs2925979, revealed no evidence of an association with MS risk (OR = 1.06; 95% CI = 
0.60, 1.88). 
 
Discussion 
In this MR study investigating the role of adiponectin level upon MS risk, we have 
demonstrated that a large (2-SD), lifelong genetic increase in adiponectin level was not 
associated with a clinically-relevant change in the odds of MS. This finding does not 
support a substantial role for adiponectin in the causal pathway of MS; however, given 
the wide confidence interval, a small protective or detrimental effect of adiponectin in 
MS cannot be definitively ruled out, and further studies will be necessary to more clearly 
ascertain adiponectin’s role. Notwithstanding, the present study suggests that a 
substantial, lifelong alteration in adiponectin levels would be necessary to influence the 
risk of disease, if adiponectin indeed plays a causal role therein. 
 
Observational studies aiming to shed light on the clinical relevance of adiponectin levels 
in MS have yielded variable results (15-18,35). Observational studies such as these are 
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susceptible to bias due to residual confounding, in addition to a number of other factors 
that may bias observational studies. While the potentially confounding effects of BMI 
were accounted for in all of these studies, there are several related, physiological effects 
which were not likely not controlled for through the use of BMI as a measure of obesity, 
and which could have influenced the reported associations. For example, differences in 
adipose tissue amount and location can influence adiponectin concentrations, as 
production of adiponectin is differentially regulated in visceral and subcutaneous 
adipocytes (36). These differences in adipose distribution are not accounted for in BMI 
calculations. Differential clearance through the liver could also influence measurements 
of adiponectin in such studies (36). One strength of the present study is that it utilizes a 
method of analysis which largely overcomes confounding, due to the random assortment 
of alleles at conception. 
 
As the present study assessed the association between lifelong genetically-increased 
adiponectin levels and the odds of development of MS, the findings reported here suggest 
that adiponectin is not an ideal preventative treatment target for MS. Adiponectin’s 
therapeutic role in MS following disease onset, on the other hand, cannot be ascertained 
based on the present findings. Interestingly, two of the adiponectin-modulating SNPs 
investigated in this study (rs601339 and rs7955516) are located near genes implicated in 
the both the preventative and therapeutic treatment of MS (GPR109A (37) and PDE3A 
(38), respectively). In addition, adiponectin treatment following EAE induction in rodents 
has been shown to attenuate the clinical course of EAE, findings suggestive of a potential 
therapeutic role of adiponectin in MS following disease onset (13). 
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Observational studies (5-8) and MR analyses (9) have indicated that increased body 
weight and BMI render individuals more susceptible to MS. As an adipokine with anti-
inflammatory properties and which is negatively correlated with BMI, adiponectin is a 
biological candidate of interest in the investigation of the underlying causal pathway of 
MS. While the present findings cannot rule out the possibility of a protective or 
detrimental role for adiponectin in MS etiology, they suggest that adiponectin’s role in 
the causal pathway of this disease is likely to be small. Further studies will be necessary 
to ascertain which biological factors drive the causal association between BMI and MS.  
 
The present study has important limitations. The possibility of residual pleiotropy biasing 
our estimates remains, despite the sensitivity analyses conducted. MR-Egger results can 
be biased when the effect on pleiotropic pathways is proportional to its effect on 
adiponectin level. Interestingly, genetic variation at adiponectin-encoding gene ADIPOQ 
was marginally associated with risk of MS (p = 0.08), and variation at this locus is less 
likely to influence MS risk independently of adiponectin than other the SNPs 
investigated. In addition, it is impossible, using current methods, to directly assess the 
extent to which canalization, or developmental compensation, may have influenced our 
results. While variation in adiponectin level explained by ADIPOGen SNPs is relatively 
high (~5%), MR relies upon the assumption of linear dose-response effects, which may 
not be suitable. It is also possible that subtle population stratification of adiponectin 
levels across Europe biased our results. Yet, no differences in adiponectin level across 
European populations in ADIPOGen, a consortium measuring adiponectin levels in 26 
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European or European-descent cohorts, were detected. Finally, as with any null finding, 
the width of the 95% confidence intervals gives a sense of what effect sizes can be 
excluded, given the large (2-SD) genetic increase in adiponectin levels. 
 
In conclusion, using data from the largest genetic consortia for adiponectin and MS, we 
find that lifelong exposure to a substantially  (2-SD) genetically-elevated adiponectin 
level has no clinically-relevant effects on MS susceptibility in individuals of European 
descent. Adiponectin is therefore not likely to be an ideal candidate target for MS 
prevention; however, its therapeutic potential for MS following disease onset remains to 
be determined. Additional studies will be necessary to ascertain which biological factors 
drive the causal association between body weight and MS. 
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